Cargando…

Prognostic Role of Tumor Budding in Breast Cancer Patients Receiving Neo-Adjuvant Therapy

Background: Isolated tumor cells or small clusters of tumor cells observed in the vicinity of the main tumor mass in pathology sections, termed tumor budding, are common in cancers and have been associated with prognosis in some settings. This study examined the clinical associations and treatment e...

Descripción completa

Detalles Bibliográficos
Autores principales: Mozarowski, Paul, Rasaiah, Bhubendra, Reed, Melissa, Lewis, Alexis, Walde, Natalie, Voutsadakis, Ioannis A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7922902/
https://www.ncbi.nlm.nih.gov/pubmed/33670512
http://dx.doi.org/10.3390/jcm10040827
_version_ 1783658792978743296
author Mozarowski, Paul
Rasaiah, Bhubendra
Reed, Melissa
Lewis, Alexis
Walde, Natalie
Voutsadakis, Ioannis A.
author_facet Mozarowski, Paul
Rasaiah, Bhubendra
Reed, Melissa
Lewis, Alexis
Walde, Natalie
Voutsadakis, Ioannis A.
author_sort Mozarowski, Paul
collection PubMed
description Background: Isolated tumor cells or small clusters of tumor cells observed in the vicinity of the main tumor mass in pathology sections, termed tumor budding, are common in cancers and have been associated with prognosis in some settings. This study examined the clinical associations and treatment efficacy implications of tumor budding in breast cancer patients receiving neo-adjuvant therapy. Methods: Breast cancer patients that received neo-adjuvant therapy before definitive surgical treatment in a single cancer center over a 7-year period were included, and their records were reviewed. Data extracted included patient demographics, tumor characteristics and pathologic response to treatment at surgery. The initial breast cancer biopsy before any therapy was reviewed by two pathologists, and a hot spot area was evaluated for tumor budding (defined as 1 to 5 cancer cells observed detached from the main tumor mass). Results: Seventy-five patients who received neo-adjuvant therapy (73 received chemotherapy and 2 received hormonal therapy) were included. Tumor budding was observed in two-thirds of the patients. There were no significant differences in patient (age and menopause status) and tumor (stage, histology and molecular sub-type equivalent) characteristics between the group that had tumor budding and the group that did not have tumor budding in the pre-treatment biopsy. Likewise, no statistically significant differences were observed in the frequency of complete or partial responses between the two groups. Conclusion: In this cohort of breast cancer patients receiving neo-adjuvant therapy, tumor budding was frequent, but it was not associated with tumor characteristics or pathologic responses to treatment. The value of tumor budding as a prognostic factor in the neo-adjuvant setting within the general breast cancer population could not be confirmed, but such a value in specific sub-groups deserves further investigation, given the pathophysiologic rationale and data from other settings.
format Online
Article
Text
id pubmed-7922902
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-79229022021-03-03 Prognostic Role of Tumor Budding in Breast Cancer Patients Receiving Neo-Adjuvant Therapy Mozarowski, Paul Rasaiah, Bhubendra Reed, Melissa Lewis, Alexis Walde, Natalie Voutsadakis, Ioannis A. J Clin Med Article Background: Isolated tumor cells or small clusters of tumor cells observed in the vicinity of the main tumor mass in pathology sections, termed tumor budding, are common in cancers and have been associated with prognosis in some settings. This study examined the clinical associations and treatment efficacy implications of tumor budding in breast cancer patients receiving neo-adjuvant therapy. Methods: Breast cancer patients that received neo-adjuvant therapy before definitive surgical treatment in a single cancer center over a 7-year period were included, and their records were reviewed. Data extracted included patient demographics, tumor characteristics and pathologic response to treatment at surgery. The initial breast cancer biopsy before any therapy was reviewed by two pathologists, and a hot spot area was evaluated for tumor budding (defined as 1 to 5 cancer cells observed detached from the main tumor mass). Results: Seventy-five patients who received neo-adjuvant therapy (73 received chemotherapy and 2 received hormonal therapy) were included. Tumor budding was observed in two-thirds of the patients. There were no significant differences in patient (age and menopause status) and tumor (stage, histology and molecular sub-type equivalent) characteristics between the group that had tumor budding and the group that did not have tumor budding in the pre-treatment biopsy. Likewise, no statistically significant differences were observed in the frequency of complete or partial responses between the two groups. Conclusion: In this cohort of breast cancer patients receiving neo-adjuvant therapy, tumor budding was frequent, but it was not associated with tumor characteristics or pathologic responses to treatment. The value of tumor budding as a prognostic factor in the neo-adjuvant setting within the general breast cancer population could not be confirmed, but such a value in specific sub-groups deserves further investigation, given the pathophysiologic rationale and data from other settings. MDPI 2021-02-18 /pmc/articles/PMC7922902/ /pubmed/33670512 http://dx.doi.org/10.3390/jcm10040827 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Mozarowski, Paul
Rasaiah, Bhubendra
Reed, Melissa
Lewis, Alexis
Walde, Natalie
Voutsadakis, Ioannis A.
Prognostic Role of Tumor Budding in Breast Cancer Patients Receiving Neo-Adjuvant Therapy
title Prognostic Role of Tumor Budding in Breast Cancer Patients Receiving Neo-Adjuvant Therapy
title_full Prognostic Role of Tumor Budding in Breast Cancer Patients Receiving Neo-Adjuvant Therapy
title_fullStr Prognostic Role of Tumor Budding in Breast Cancer Patients Receiving Neo-Adjuvant Therapy
title_full_unstemmed Prognostic Role of Tumor Budding in Breast Cancer Patients Receiving Neo-Adjuvant Therapy
title_short Prognostic Role of Tumor Budding in Breast Cancer Patients Receiving Neo-Adjuvant Therapy
title_sort prognostic role of tumor budding in breast cancer patients receiving neo-adjuvant therapy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7922902/
https://www.ncbi.nlm.nih.gov/pubmed/33670512
http://dx.doi.org/10.3390/jcm10040827
work_keys_str_mv AT mozarowskipaul prognosticroleoftumorbuddinginbreastcancerpatientsreceivingneoadjuvanttherapy
AT rasaiahbhubendra prognosticroleoftumorbuddinginbreastcancerpatientsreceivingneoadjuvanttherapy
AT reedmelissa prognosticroleoftumorbuddinginbreastcancerpatientsreceivingneoadjuvanttherapy
AT lewisalexis prognosticroleoftumorbuddinginbreastcancerpatientsreceivingneoadjuvanttherapy
AT waldenatalie prognosticroleoftumorbuddinginbreastcancerpatientsreceivingneoadjuvanttherapy
AT voutsadakisioannisa prognosticroleoftumorbuddinginbreastcancerpatientsreceivingneoadjuvanttherapy